CAS 1191951-57-1
:4-Dodecyl-N-1,3,4-thiadiazol-2-ylbenzolsulfonamid
- 4-Dodecyl-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide
- Benzenesulfonamide, 4-dodecyl-N-1,3,4-thiadiazol-2-yl-
- PHT 427
Benzenesulfonamide, 4-dodecyl-N-1,3,4-thiadiazol-2-yl-
CAS:Formel:C20H31N3O2S2Reinheit:98%Farbe und Form:SolidMolekulargewicht:409.60904-Dodecyl-N-(1,3,4-Thiadiazol-2-Yl)Benzenesulfonamide
CAS:4-Dodecyl-N-(1,3,4-Thiadiazol-2-Yl)BenzenesulfonamideReinheit:98%Molekulargewicht:409.61g/molPHT-427
CAS:PHT-427 (CS-0223) is a dual Akt (Ki: 2.7 μM) and PDPK1 (Ki: 5.2 μM) inhibitor (high-affinity binding for the PH domains of Akt and PDPK1).Formel:C20H31N3O2S2Reinheit:97.54% - >99.99%Farbe und Form:SolidMolekulargewicht:409.61PHT-427
CAS:Kontrolliertes ProduktApplications PHT-427 is a pleckstrin homology domain inhibitor to Akt and PKB Kinase (PDPK1). It can also be used for therapeutic use and biological study of mathematical modeling and parametric analysis of nanoparticle encapsulation and controlled release of a hydrophobic kinase inhibitor PHT-427.
References Lucero-Acuna, A., et al.: Int J Pharm, 494, 249 (2015)Formel:C20H31N3O2S2Farbe und Form:NeatMolekulargewicht:409.61PHT-427-d4 (Major)
CAS:Kontrolliertes ProduktFormel:C20H27D4N3O2S2Farbe und Form:NeatMolekulargewicht:413.63Akt Inhibitor XIV
CAS:Akt Inhibitor XIV is a growth factor that regulates cell maturation and protein synthesis. Akt inhibitor XIV has been shown to inhibit the activity of CDK4/6, which are enzymes involved in the control of cell cycle progression. This compound has minimal toxicity, can be taken orally, and has been shown to inhibit tumor growth in xenografts. It is an analog of rapamycin and may also have similar anti-cancer effects as rapamycin.
Formel:C20H31N3O2S2Reinheit:Min. 95%Molekulargewicht:409.61 g/molRef: 3D-RXB95157
Ausgelaufenes produkt





